NCT01556789View on ClinicalTrials.gov

Phase 1 Study of ONT-10 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

September 30, 2015

Conditions
Solid Tumors
Interventions
BIOLOGICAL

ONT-10

ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.

Trial Locations (3)

75201

Mary Crowley Cancer Research Center, Dallas

80045

University of Colorado Cancer Center, Aurora

98405

Northwest Medical Specialties, PLLC, Tacoma

Sponsors
All Listed Sponsors
lead

Cascadian Therapeutics Inc.

INDUSTRY

NCT01556789 - Phase 1 Study of ONT-10 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter